New Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Accumulating evidence has shown a strong relationship between Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), and cerebrovascular disease. Cognitive impairment in AD patients can result from cortical microinfarcts associated with CAA, as well as the synaptic and neuronal disturbances caused by cerebral accumulations of β-amyloid (Aβ) and tau proteins. The pathophysiology of AD may lead to a toxic chain of events consisting of Aβ overproduction, impaired Aβ clearance, and brain ischemia. Insufficient removal of Aβ leads to development of CAA and plays a crucial role in sporadic AD cases, implicating promotion of Aβ clearance as an important therapeutic strategy. Aβ is mainly eliminated by three mechanisms: (1) enzymatic/glial degradation, (2) transcytotic delivery, and (3) perivascular drainage (3-"d" mechanisms). Enzymatic degradation may be facilitated by activation of Aβ-degrading enzymes such as neprilysin, angiotensin-converting enzyme, and insulin-degrading enzyme. Transcytotic delivery can be promoted by inhibition of the receptor for advanced glycation end products (RAGE), which mediates transcytotic influx of circulating Aβ into brain. Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a Phase III clinical trial for AD patients. The perivascular drainage system seems to be driven by motive force generated by cerebral arterial pulsations, suggesting that vasoactive drugs can facilitate Aβ clearance. One of the drugs promoting this system is cilostazol, a selective inhibitor of type 3 phosphodiesterase. The clearance of fluorescent soluble Aβ tracers was significantly enhanced in cilostazol-treated CAA model mice. Given that the balance between Aβ synthesis and clearance determines brain Aβ accumulation, and that Aβ is cleared by several pathways stated above, multi-drugs combination therapy could provide a mainstream cure for sporadic AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60240-2 · Cited by 6,972
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Insufficient Aβ clearance seems to be more crucial than Aβ overproduction in sporadic AD patients (Mawuenyega et al., 2010).”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 3×
“Strong staining for RAGE has been reported in the vessels of AD patients (Yan et al., 1996; Donahue et al., 2006) and has been shown to mediate influx of circulating Aβ into brain across the BBB (Deane et al.”
BackgroundMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“Aβ accumulation and other AD changes are also recognized in elderly patients without apparent dementia (Funato et al., 1998; Schneider et al., 2007), which implies a strong relationship between AD neuropathology and the aging processes.”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590 · cited 2×
“The Nun study revealed that CVD plays an important role in determining the presence and severity of the clinical symptoms of AD (Snowdon et al., 1997).”
BackgroundInfluentialShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 6×
“The relationship is further supported by reduced LRP-1 staining in vessels both in AD patients (Shibata et al., 2000; Donahue et al., 2006) and CAA model mice carrying a vasculotropic Dutch/Iowa mutant form of APP gene (Deane et al., 2004).”
BackgroundInfluential(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Cerebral Arterial Pulsation Drives Paravascular CSF–Interstitial Fluid Exchange in the Murine Brain
Iliff, J. J., Wang, M., Zeppenfeld, D. M., Venkataraman, A., Plog, B. A., Liao, Y., Deane, R., & Nedergaard, M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1592-13.2013 · Cited by 1,319
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 1×
“Some researchers have labeled AD “type 3 diabetes” (de la Monte and Wands, 2008).”
BackgroundNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · cited 1×
“Colocalization of LRP-1 with Aβ was pathologically recognized in senile plaques (Rebeck et al., 1993; Donahue et al., 2006), strengthening the linkage.”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · cited 2×
“Several authors have proposed ApoE as therapeutic target for Aβ clearance (Cramer et al., 2012; Zolezzi and Inestrosa, 2014).”
BackgroundInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 2×
“Thus, dementia patients with a single simple etiology are scarcely seen, except for juvenile familial AD cases caused by mutations in the APP or presenilin genes, comprising <1% of AD cases (Campion et al., 1999).”
BackgroundApolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · cited 2×
“ApoE immunoreactivity is common in amyloid plaques, suggesting that ApoE interacts with Aβ directly in AD brains and could strongly influence the rate of Aβ removal (Namba et al., 1991; Holtzman et al., 2012).”
BackgroundNedergaard, M. (2013) · Science · doi:10.1126/science.1240514 · Cited by 718
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 1×
“Indeed, a RAGE inhibitor ameliorated cerebral Aβ burden and normalized cognitive performance in APP-transgenic mice (Deane et al., 2012).”
BackgroundCharidimou, A., Gang, Q., & Werring, D. J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301308 · Cited by 611 · cited 3×
“, 2006), this necessitates the use of antiplatelet drugs with little risk of hemorrhage (Charidimou et al., 2012).”
BackgroundHypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression
Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., & Song, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606298103 · Cited by 605 · cited 1×
“Brain ischemia and hypoxia modulates amyloid precursor protein (APP) cleavage enzymes such as β-secretase and γ-secretase, thereby resulting in increased Aβ production (Sun et al., 2006; Guglielmotto et al., 2009; Kitaguchi et al., 2009; Li et al., 2009).”
BackgroundRAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Lymphatic drainage of the brain and the pathophysiology of neurological disease
Weller, R. O., Djuanda, E., Yow, H.-Y., & Carare, R. O. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0457-0 · Cited by 488
Cerebral microinfarcts: the invisible lesions
Smith, E. E., Schneider, J. A., Wardlaw, J. M., & Greenberg, S. M. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70307-6 · Cited by 456
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 1×
“Rolipram, a PDE4 inhibitor, reverses the decrease in cAMP regulatory element-binding protein (CREB) phosphorylation, which results in persistent improvement in synaptic function in AD model mice (Gong et al., 2004).”
BackgroundMidlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Vascular risk factors and dementia: How to move forward?
Viswanathan, A., Rocca, W. A., & Tzourio, C. (2009) · Neurology · doi:10.1212/01.wnl.0000341271.90478.8e · Cited by 414
Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit
Bradbury, M. W., Cserr, H. F., & Westrop, R. J. (1981) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1981.240.4.f329 · Cited by 335
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Mechanisms to explain the reverse perivascular transport of solutes out of the brain
Schley, D., Carare-Nnadi, R., Please, C. P., Perry, V. H., & Weller, R. O. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.07.005 · Cited by 293 · cited 1×
“Theoretical models have indicated that arterial pulsations could be the motive force behind ISF and solutes being driven centrifugally from the brain by reflection waves that follow each cardiac pulse wave (Schley et al., 2006).”
BackgroundChanging perspectives regarding late-life dementia
Fotuhi, M., Hachinski, V., & Whitehouse, P. J. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.175 · Cited by 291
Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts
Okamoto, Y., Yamamoto, T., Kalaria, R. N., Senzaki, H., Maki, T., Hase, Y., Kitamura, A., Washida, K., Yamada, M., Ito, H., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0925-9 · Cited by 249 · cited 2×
“, 2011), and after bilateral common carotid artery stenosis (Okamoto et al., 2012), further supports the notion that brain ischemia and impaired arterial pulsation could be an exacerbation factor of CAA.”
BackgroundSelf-citationTreatment of vascular risk factors is associated with slower decline in Alzheimer disease
Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59bf3 · Cited by 232 · cited 2×
“AD and CVD share common risk factors (Viswanathan et al., 2009; Kalaria et al., 2012), and treatment of vascular risk factors is associated with slower decline in cognitive impairments of AD patients (Deschaintre et al., 2009).”
BackgroundCarare, R. O., Hawkes, C. A., Jeffrey, M., Kalaria, R. N., & Weller, R. O. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12042 · Cited by 207 · cited 3×
“The perivascular lymphatic drainage system, one of the Aβ clearance mechanisms, is closely associated with AD and CAA (Carare et al., 2013).”
BackgroundCerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy
Verbeek, M. M., Kremer, B. P. H., Rikkert, M. O., Van Domburg, P. H. M. F., Skehan, M. E., & Greenberg, S. M. (2009) · Annals of Neurology · doi:10.1002/ana.21694 · Cited by 202
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 1×
“However, brain ACE deficient mice showed no significant alteration in endogenous Aβ levels (Eckman et al., 2006).”
BackgroundIn Vivo Detection of Cerebral Cortical Microinfarcts with High-Resolution 7T MRI
van Veluw, S. J., Zwanenburg, J. J., Engelen-Lee, J., Spliet, W. G., Hendrikse, J., Luijten, P. R., & Biessels, G. J. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.196 · Cited by 193 · cited 1×
“In addition, imaging technology advances, including 7 T MRI, have identified numerous cortical microinfarcts (CMI), which have been attributed to CAA (Suter et al., 2002; van Veluw et al., 2013; Westover et al., 2013).”
BackgroundCerebrovascular lesions induce transient -amyloid deposition
Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., Frosch, M. P., Greenberg, S. M., & Bacskai, B. J. (2011) · Brain · doi:10.1093/brain/awr300 · Cited by 187
Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. (2013) · Science · doi:10.1126/science.1235809 · Cited by 151
Han, B. H., Zhou, M.-L., Abousaleh, F., Brendza, R. P., Dietrich, H. H., Koenigsknecht-Talboo, J., Cirrito, J. R., Milner, E., Holtzman, D. M., & Zipfel, G. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4686-08.2008 · Cited by 138
Price, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138
Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J. K., Rajapaksha, T. W., Ulrich, J., Jucker, M., Holtzman, D. M., Tanzi, R. E., Vassar, R., et al. (2013) · Science · doi:10.1126/science.1235505 · Cited by 133 · cited 1×
“However, some conflicting reports have been also documented (Fitz et al., 2013; Price et al., 2013; Tesseur et al., 2013; Veeraraghavalu et al., 2013).”
ResultTesseur, I., Lo, A. C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., Moechars, D., Mercken, M., Kemp, J., et al. (2013) · Science · doi:10.1126/science.1233937 · Cited by 128
Shinkai, Y., Yoshimura, M., Ito, Y., Odaka, A., Suzuki, N., Yanagisawa, K., & Ihara, Y. (1995) · Annals of Neurology · doi:10.1002/ana.410380312 · Cited by 127 · cited 1×
“Tissue soluble Aβ was detected by enzyme immunoassay in meningeal arteries and intracranial arteries but not in extracranial vessels (Shinkai et al., 1995).”
MethodEstimating cerebral microinfarct burden from autopsy samples
Westover, M. B., Bianchi, M. T., Yang, C., Schneider, J. A., & Greenberg, S. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31828c2f52 · Cited by 122 · cited 1×
“In addition, imaging technology advances, including 7 T MRI, have identified numerous cortical microinfarcts (CMI), which have been attributed to CAA (Suter et al., 2002; van Veluw et al., 2013; Westover et al., 2013).”
BackgroundOriglia, N., Bonadonna, C., Rosellini, A., Leznik, E., Arancio, O., Yan, S. S., & Domenici, L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2127-10.2010 · Cited by 111 · cited 1×
“In addition, RAGE contributes to Aβ-related synaptic dysfunction and microglial activation (Yan et al., 1996; Origlia et al., 2008, 2010).”
BackgroundChronic cerebral hypoperfusion accelerates amyloid β deposition in APPSwInd transgenic mice
Kitaguchi, H., Tomimoto, H., Ihara, M., Shibata, M., Uemura, K., Kalaria, R. N., Kihara, T., Asada-Utsugi, M., Kinoshita, A., & Takahashi, R. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.078 · Cited by 108
Self-citationRozzini, L., Chilovi, B. V., Bertoletti, E., Conti, M., Rio, I. D., Trabucchi, M., & Padovani, A. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1523 · Cited by 93 · cited 1×
“In addition, two small studies assessing the clinical use of ACE inhibitors, found that they did not deteriorate dementia in AD and amnestic mild cognitive impairment (MCI) patients (Ohrui et al., 2004; Rozzini et al., 2006).”
Background
Cited by
Emerging concepts in sporadic cerebral amyloid angiopathy
Charidimou, A., Boulouis, G., Gurol, M. E., Ayata, C., Bacskai, B. J., Frosch, M. P., Viswanathan, A., & Greenberg, S. M. (2017) · Brain · doi:10.1093/brain/awx047 · Cited by 555
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 558
Oxidative Stress in Health and Disease
Reddy, V. P. (2023) · Biomedicines · doi:10.3390/biomedicines11112925 · Cited by 333
Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
Castillo-Carranza, D. L., Nilson, A. N., Van Skike, C. E., Jahrling, J. B., Patel, K., Garach, P., Gerson, J. E., Sengupta, U., Abisambra, J., Nelson, P., et al. (2017) · Aging and disease · doi:10.14336/ad.2017.0112 · Cited by 118
Saito, S., Yamamoto, Y., Maki, T., Hattori, Y., Ito, H., Mizuno, K., Harada-Shiba, M., Kalaria, R. N., Fukushima, M., Takahashi, R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0429-5 · Cited by 110
“Taxifolin maintained cerebrovascular integrity in Tg-SwDI mice, which might facilitate vascular-mediated removal of amyloid-β from the brain [58].”
BackgroundSelf-citation
Metadata
- Authors
- Saito, S., & Ihara, M.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-10-20
- Volume
- 6
- Pages
- 290-290
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W1574564357
- Cited by
- 73
- References
- 53
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.